Our results revealed the potential role of PSMA PET/CT in the staging or evaluation of primary RCC lesions and in the restaging of metastatic or recurrent RCC, with a pooled detection rate of 0.74 (95% CI, 0.57–0.86) and 0.87 (95% CI, 0.73–0.95), respectively. This evidence concerns the gene FOLH1 and renal cell carcinoma.